Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. (2r,3s)-n-((3s)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1h-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide
2. Bms-986115
3. Butanediamide, N1-((3s)-5-(3-fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1h-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)-, (2r,3s)-
1. Bms-986115
2. 1584647-27-7
3. Notch Inhibitor 1
4. Bms 986115
5. Lsk1l593uu
6. (2s,3r)-n'-[(3s)-5-(3-fluorophenyl)-9-methyl-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide
7. Chembl3911164
8. Schembl15608290
9. Bms986115
10. Nsc836050
11. Bms 986115 [who-dd]
12. Db13126
13. Nsc-836050
14. (2r,3s)-n-((3s)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1h-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide
15. Hy-12860
16. Cs-0012731
17. P14960
18. Us9273014, 1
19. Q27283163
20. (2r,3s)-n1-((s)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide
21. Butanediamide, N1-((3s)-5-(3-fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1h-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)-, (2r,3s)-
Molecular Weight | 574.5 g/mol |
---|---|
Molecular Formula | C26H25F7N4O3 |
XLogP3 | 4.8 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 9 |
Exact Mass | 574.18148781 g/mol |
Monoisotopic Mass | 574.18148781 g/mol |
Topological Polar Surface Area | 114 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 956 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Gamma Secretase Inhibitors and Modulators
Agents that suppress GAMMA-SECRETASE by inhibiting or modulating its activities. Targeted enzymatic activities include its involvement in accumulation of toxic AMYLOID BETA-PEPTIDES (e.g., Aβ42) in ALZHEIMER DISEASE and activation of NOTCH RECEPTOR mediated SIGNAL PATHWAYS in certain cancer types. (See all compounds classified as Gamma Secretase Inhibitors and Modulators.)
ABOUT THIS PAGE
45
PharmaCompass offers a list of BMS-986115 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right BMS-986115 manufacturer or BMS-986115 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred BMS-986115 manufacturer or BMS-986115 supplier.
PharmaCompass also assists you with knowing the BMS-986115 API Price utilized in the formulation of products. BMS-986115 API Price is not always fixed or binding as the BMS-986115 Price is obtained through a variety of data sources. The BMS-986115 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Varegacestat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Varegacestat, including repackagers and relabelers. The FDA regulates Varegacestat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Varegacestat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Varegacestat supplier is an individual or a company that provides Varegacestat active pharmaceutical ingredient (API) or Varegacestat finished formulations upon request. The Varegacestat suppliers may include Varegacestat API manufacturers, exporters, distributors and traders.
Varegacestat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Varegacestat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Varegacestat GMP manufacturer or Varegacestat GMP API supplier for your needs.
A Varegacestat CoA (Certificate of Analysis) is a formal document that attests to Varegacestat's compliance with Varegacestat specifications and serves as a tool for batch-level quality control.
Varegacestat CoA mostly includes findings from lab analyses of a specific batch. For each Varegacestat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Varegacestat may be tested according to a variety of international standards, such as European Pharmacopoeia (Varegacestat EP), Varegacestat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Varegacestat USP).